Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 46

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 46
---
b clinical trial in PBC to complete enrollment in 2026.

To date, we have focused primarily on acquiring and in-licensing our product candidates, organizing
and staffing our company, business planning, raising capital, advancing our product candidates through clinical development, preparing for commercialization of our product candidates, commercializing our approved medicines, and conducting business
development activities relating to, among other things, portfolio expansion through collaborations and acquisitions.

Corporate Information

We were incorporated in Delaware in May 2018. Our principal executive offices are located at 989 East Hillsdale Boulevard, Suite 300, Foster
City, California 94404, and our telephone number is (650) 667-4085. Our corporate website address is ir.mirumpharma.com. Our website and the information contained on, or that can be accessed through, our
website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus supplement or the accompanying prospectus. Our design logo, “Mirum,” and our other registered and common law trade names,
trademarks and service marks are the property of Mirum Pharmaceuticals, Inc.

S-3

The Offering

| Common stock offered by us | In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock from time to time through or to Leerink Partners and Cantor having an aggregate offering price of up to $200,000,000. |

| Common stock to be outstanding after this offering | Up to 53,094,675 shares (as more fully described in the notes following this table), assuming sales of 3,036,283 shares of our common stock in this offering at an assumed offering price of $65.87 per share, which was the last                 
 reported sale price of our common stock on the Nasdaq Global Market on August 11, 2025. The actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur. |

| Plan of distribution | “At the market offering” that may be made from time to time through or to Leerink Partners and Cantor as our sales agents or principals. See “Plan of Distribution” on page S-13 of this prospectus supplement. |

| Use of proceeds | We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including working capital, operating expenses and capital expenditures. See “Use of Proceeds” on